LY 223982

Leukotriene B₄ (LTB₄) is a dihydroxy fatty acid derived from the 5-lipoxygenase pathway of arachidonic acid metabolism and is an important mediator of the inflammatory process. The benzophenone dicarboxylic acid derivative LY223982 is a potent BLT₁ receptor antagonist. It inhibits the specific binding of radiolabeled-LTB₄ to isolated human neutrophils with an IC₅₀ value of 13.2 nM. LY223982 inhibits the leukotriene B₄ (LTB₄)-induced aggregation of guinea pig and human neutrophils with IC₅₀ values of 74 and 100 nM, respectively. However, concentrations of LY223982 up to 10 μM do not inhibit binding of LTB₄ to human BLT₁ or BLT₂ expressed in CHO cells.

LY223982 is a potent P2Y7 (BLT1) receptor antagonist.

LTB₄: 13.2 nM (IC₅₀)

[1] D. MARK GAPINSKI. Benzophenone dicarboxylic acid antagonists of leukotriene B4. 2. Structure-activity relationships of the lipophilic side chain[J]. Journal of Medicinal Chemistry, 1990, 33 10: 2807-2813. DOI: 10.1021/jm00172a020
[2] W T JACKSON. Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982.[J]. Journal of Pharmacology and Experimental Therapeutics, 1992, 263 3: 1009-1014.
[3] T. YOKOMIZO. Hydroxyeicosanoids Bind to and Activate the Low Affinity Leukotriene B4 Receptor, BLT2*[J]. The Journal of Biological Chemistry, 2001, 3 1: 12454-12459. DOI: 10.1074/jbc.m011361200